Exploring the Impact of Psoriasis on Quality of Life and Information-seeking Behaviors: Insights into Severity, Symptoms, Patient Perspectives, and Sources of Information
This report provides a behind-the-scenes look at quality of life for those living with psoriasis. Using detailed quantitative data, it provides insight into the condition status story - from symptoms to impact on life to information-seeking behaviors - so you can make informed, strategic decisions, identify opportunities, and understand potential challenges.
Approximately 7.5 million people in the United States have psoriasis.
Psoriasis in America 2023: Quality of Life & Information-Seeking Behaviors offers a glimpse into quality of life for people living with psoriasis. It includes selected insights for stakeholders seeking a more focused view of life impact and information-seeking behaviors. For the complete report (including additional data on treatment awareness and satisfaction), please see Psoriasis in America 2023: Understanding the Psoriasis Patient Experience.
This large-scale, patient-reported data leverages vital quantitative insights for understanding how patients seek out information, what content they’re interested in, and the overall impact on life after an psoriasis diagnosis.
What makes this report unique?
Very simply: the focus on patients. This syndicated report is one of the few studies that is based on primary research with diagnosed patients, bringing the patient voice to the forefront.
Valuable insights. Informed decisions.
This report lifts the curtain on life with psoriasis, giving stakeholders an actionable look at the behaviors, attitudes, perceptions, needs, and experiences of people diagnosed with the condition. Data can be used to inform strategic decisions, including product communications, concept development, patient journey overlays, and forecasting inputs.
This report also addresses important questions that stakeholders may not even know to ask while offering valuable insights into must-have patient-reported data points not available anywhere else. Add-on custom data analysis opportunities are also available for an additional cost - please see the report following purchase for more information.
The analyst reaches millions of people through its portfolio of 45+ condition-specific online health communities - including PlaquePsoriasis.com - to provide information, connection, and support to patients and caregivers in the U.S.
This report includes a deep-dive into:
- Impact of psoriasis on quality of life
- Severity, impact on quality of life, symptoms experienced, and what patients wish others better understood
- Information-seeking behaviors
- Information sources used, plus topics of interest
Key questions answered in this report:
- To what extent do people say psoriasis impacts their overall quality of life?
- What’s the average number of flares in the past year?
- What do patients wish others understood about psoriasis?
- What are the top online resources people with psoriasis use to find information?
- What kinds of psoriasis content and information do patients search for?
- What percentage of patients search for information on treatment options?
Methodology
Psoriasis in America 2023: Quality of Life & Information-Seeking Behaviors consists of:
- A 20-minute online quantitative survey
- Qualitative patient insights from open-ended responses
Additional details:
- Fielded: January 16, 2023 to April 14, 2023
- Convenience sample of 490 respondents diagnosed with psoriasis
- Respondents are age 18+, living in the U.S., and are recruited from proprietary online health communities and recruiting partners
Table of Contents
Methodology
Respondent Demographic Highlights
Treatment Awareness and Experiences
- Primary HCP Seen for Psoriasis Care
- Aided Brand Awareness of Treatments
- Treatment Usage
- Condition Control on Current Treatment
- Clinical Trial Interest
- Treatment Discussions with HCP
Appendix with Associated Data Charts and Distributions
Products Mentioned
Brands and treatments mentioned in this report include:
- Topical corticosteroid (such as hydrocortisone)
- BRYHALI™ (halobetasol propionate) lotion
- DesOwen® (desonide)
- SERNIVO™ (betamethasone dipropionate)
- SORILUX™ Foam (calcipotriene)
- TACLONEX® (calcipotriene and betamethasone)
- TAZORAC® (tazarotene)
- VECTICAL® (calcitriol)
- VTAMA® (tapinarof)
- ZITHRANOL™-RR (anthralin)
- ZORYVE™ (roflumilast)
- Acitretin (SORIATANE®)
- ARAVA® (leflunomide)
- Azathioprine (such as IMURAN®, AZASAN®)
- Cyclosporine (such as Sandimmune®, NEORAL®, RESTASIS®)
- Methotrexate (eg, Rheumatrex®), also sometimes given as an injection
- OTEZLA® (apremilast)
- PLAQUENIL® (hydroxychloroquine)
- RINVOQ® (upadacitinib)
- SOTYKTU™ (deucravacitinib)
- Sulfasalazine (Azulfidine®)
- XELJANZ®/XELJANZ® XR (tofacitinib citrate)
- AMJEVITA™ (adalimumab-atto) Hide until launched in US
- AVSOLA® (infliximab-axxq)
- CIMZIA® (certolizumab)
- COSENTYX® (secukinumab)
- CYLTEZO® (adalimumab-adbm) Hide until launched in US
- ENBREL® (etanercept)
- ERELZI™ (etanercept-szzs) Hide until launched in US
- HULIO® (adalimumab-fkjp) Hide until launched in US
- HUMIRA® (adalimumab)
- HYRIMOZ® (adalimumab-adaz) Hide until launched in US
- ILUMYA™ (tildrakizumab-asmn)
- INFLECTRA® (infliximab-dyyb)
- IXIFI™ (infliximab-qbtx) Hide until launched in US
- ORENCIA® (abatacept)
- REMICADE® (infliximab)
- RENFLEXIS™ (infliximab-abda)
- SIMPONI® (golimumab)
- SIMPONI ARIA® (golimumab for infusion)
- SILIQ™ (brodalumab)
- SKYRIZI® (risankizumab-rzaa)
- STELARA® (ustekinumab)
- TALTZ® (ixekizumab)
- TREMFYA® (guselkumab)
